Laboratory Genetic Metabolic Diseases (F0-222), Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Am J Med Genet C Semin Med Genet. 2012 Nov 15;160C(4):263-84. doi: 10.1002/ajmg.c.31346. Epub 2012 Oct 5.
Smith-Lemli-Opitz syndrome (SLOS; OMIM #270400) is an autosomal recessive malformation syndrome characterized by a large spectrum of morphogenic and congenital anomalies. SLOS is caused by mutations in the DHCR7 gene, which encodes 7-dehydrocholesterol reductase, the enzyme that catalyzes the final step in cholesterol biosynthesis. We report on 154 currently known mutations in DHCR7 identified in patients affected with SLOS and discuss their coding consequences. These 154 mutations include 130 missense, 8 nonsense, 8 deletions, 2 insertions, 1 indel, and 5 splice site mutations. Using information available from published case reports and from patients identified in our clinical diagnostic laboratory, we analyzed correlations between genotype, clinical presentation and 7-dehydrocholesterol level.
史密斯-莱姆利-奥皮茨综合征(SLOS;OMIM#270400)是一种常染色体隐性遗传的畸形综合征,其特征是具有广泛的形态发生和先天性异常。SLOS 是由 DHCR7 基因突变引起的,该基因突变编码 7-脱氢胆固醇还原酶,该酶催化胆固醇生物合成的最后一步。我们报告了在患有 SLOS 的患者中发现的 154 个目前已知的 DHCR7 突变,并讨论了它们的编码后果。这些 154 个突变包括 130 个错义突变、8 个无义突变、8 个缺失突变、2 个插入突变、1 个插入缺失突变和 5 个剪接位点突变。利用来自已发表的病例报告和我们临床诊断实验室中鉴定的患者的可用信息,我们分析了基因型、临床表现和 7-脱氢胆固醇水平之间的相关性。